Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

The Italian subsidiary of Swiss drug maker Roche manufactures all of the company's most successful medications -- hepatitis B and C drug Pegasys, cancer drugs Herceptin and Avastin, and MabThera, for non-Hodgkin lymphoma. Roche S.p.A.'s business is roughly 40% oncology and hematology, 30% specialty care (Pegasys, Neorecormon, Copegus), and 30% primary care (analgesics, antibiotics). Its 700,000-square-foot production facility in Segrate, a town near Milan in northern Italy, produces almost 1,400 tons of medication every year, about 60% of which is exported across Europe.

Thallion Pharmaceuticals develops products for the treatment of cancer and infections. Thallion has three leading products in various developmental stages. The Shigamabs drug candidate is targeted to treat Shigatoxin producing E. coli infections. The company's TLN-232 is being evaluated as a treatment of a number of cancer conditions. Its TLN-4601 is another oncology focused treatment. Thallion was considering the possible sale of the company until it received a nearly $9 million capital infusion through an arrangement with Premium Brands. Though Thallion's operations didn't change, and it's still owned by the same shareholders, the move did take the company public.

Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Alfacell Corporation was founded in 1981 and is headquartered in Somerset, New Jersey. Alfacell Corporation, a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company's lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also focuses on new drug application for unresectable malignant mesothelioma. In addition, the company completed a Phase I clinical trial for the treatment of non-small cell lung cancer.

Avacta will take a closer look and get back with you. The biophysics company makes its money from the exact science of detecting molecules. Its Avacta Analysis arm provides analytical and research services to the pharmaceutical, healthcare, and personal care industries. It also offers expert witness services to assist in pharmaceutical patent disputes and suspected counterfeiting cases. The company's technology arm has developed a product to help drug developers analyze and predict the potential usefulness of biological drug compounds. The company also owns veterinary laboratory services provider YorkTest Veterinary Services, and diagnostic test maker Curidium Medica.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Merck & Co., Inc. company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. Merck & Co., Inc. provides products for human and animal health primarily in the United States. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting.Merck & Co.'s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; Addex Pharmaceuticals Ltd.; and Nuevolution A/S.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.